Literature DB >> 32347647

A comparative evaluation of dexmedetomidine and midazolam in pediatric sedation: A meta-analysis of randomized controlled trials with trial sequential analysis.

Bingchen Lang1,2,3, Lingli Zhang1,2,3, Wensheng Zhang4, Yunzhu Lin1,2,3, Yuzhi Fu1,2,3, Shouming Chen5.   

Abstract

BACKGROUND: The present study with trial sequential analysis (TSA) was conducted to evaluate comprehensively the efficacy and safety of dexmedetomidine and midazolam in pediatric sedation, and to investigate whether the outcomes achieved the required information size to draw the conclusions.
METHODS: PubMed, Embase, and Cochrane Library were searched from inception to October 2019. All randomized controlled trials used dexmedetomidine and midazolam in pediatric sedation were enrolled. Sedative efficacy, postoperative analgesic effect, and incidence of emergence agitation were considered as the co-primary outcomes. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to rate the quality of evidences.
RESULTS: We acquired data from 34 studies involving 2281 pediatric patients. The results indicated that administration of dexmedetomidine was associated with less incidence of emergence agitation (RR = 0.78, with 95% CI [0.65, 0.92]) and more satisfactory sedation at parental separation (RR = 0.31, with 95% CI [0.24, 0.41]) compared to midazolam, and the current sample sizes were sufficient with unnecessary further trials. Two groups did not differ significantly in sedation level at mask induction (RR = 0.86, with 95% CI [0.74, 1.00]). And using of dexmedetomidine was associated with less incidence of postoperative analgesic rescue (RR = 0.57, with 95% CI [0.35, 0.93]), but the number of patients was too few to achieve the required information size and to draw reliable conclusions. Premedication of dexmedetomidine was associated with significant less value of SBP, heart rate, increased incidence of bradycardia, and a lower rate of shivering. And there were no differences about onset of sedation and recovery time between two groups.
CONCLUSIONS: Given that more satisfactory sedation at separation from parents and less incidence of emergence agitation, dexmedetomidine is preferred for pediatric sedation. However, compared with midazolam, the superiority of dexmedetomidine in providing adequate sedation at mask induction and postoperative analgesic effects has not yet been defined.
© 2020 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

Entities:  

Keywords:  dexmedetomidine; meta-analysis; midazolam; pediatrics; sedation

Year:  2020        PMID: 32347647     DOI: 10.1111/cns.13377

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  5 in total

Review 1.  Perioperative neurocognitive disorders: A narrative review focusing on diagnosis, prevention, and treatment.

Authors:  Hao Kong; Long-Ming Xu; Dong-Xin Wang
Journal:  CNS Neurosci Ther       Date:  2022-06-01       Impact factor: 7.035

2.  Efficacy of Dexmedetomidine Anesthesia plus Dorsal Penile Nerve Block in Pediatric Circumcision.

Authors:  Ling Ji; Fan Yao; Yanwu Wang; Caishun Li; Yulong Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-30       Impact factor: 2.650

3.  The Sedative Effects of Inhaled Nebulized Dexmedetomidine on Children: A Systematic Review and Meta-Analysis.

Authors:  Jun Lin; Chujun Wu; Dizhou Zhao; Xuhang Du; Wangzhi Zhang; Jieyu Fang
Journal:  Front Pediatr       Date:  2022-05-20       Impact factor: 3.569

4.  Effect of different administration and dosage of dexmedetomidine in the reduction of emergence agitation in children: a meta-analysis of randomized controlled trials with sequential trial analysis.

Authors:  Xu Zhang; Yan Bai; Min Shi; Shaopeng Ming; Xiaogao Jin; Yubo Xie
Journal:  Transl Pediatr       Date:  2021-04

5.  Development and validation of prediction models for neurocognitive disorders in adult patients admitted to the ICU with sleep disturbance.

Authors:  Yun Li; Lina Zhao; Ye Wang; Xizhe Zhang; Jiannan Song; Qi Zhou; Yi Sun; Chenyi Yang; Haiyun Wang
Journal:  CNS Neurosci Ther       Date:  2021-12-23       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.